Testing DISP-10 for Advanced Gastrointestinal Cancers
Part of Cancer, Digestive system, Infections clinical trials.
This early-stage trial tests a new experimental therapy called DISP-10 in patients with advanced cancers of the stomach, esophagus, or colon that have spread. The goal is to see if this treatment can help shrink tumors and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of advanced or spread esophageal, gastric, or colorectal cancer
- Your cancer can be seen on imaging and you have at least one tumor spot that doctors can safely biopsy
- You are in good enough health to handle the treatment (ECOG score 0 or 1, meaning you can do normal activities or have some limitations)
- You are at least 18 years old
- Your liver, kidneys, and blood counts are healthy enough for the study
- You have not had an organ or bone marrow transplant in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (DSP107 and atezolizumab) compared to another drug (fruquintinib) for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to find a more effective treatment option.
This early-stage trial tests a new drug called IDP-001 in people with advanced cancers that have spread or cannot be surgically removed. The study aims to find the right dose and see how well the drug works against various solid tumors.
This Phase 1 trial tests DFP-14927, a new study drug, in adults with advanced solid tumors that have not responded to standard treatments. It’s designed to see if the drug is safe and to learn how it works in people with limited treatment options.
This trial tests a new immunotherapy drug (STC-1010) for people with colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the drug can shrink tumors or slow the disease.
This trial tests a new drug called 7MW4911 for people with advanced gastrointestinal cancer that has not responded to standard treatments. The drug is designed to target and attack cancer cells, and doctors will check if it is safe and effective.
This trial tests a new oral drug, DAT-1604, for people with advanced solid tumors who have run out of standard options. The goal is to see if it is safe, how the body processes it, and whether it can shrink tumors.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.